Jennifer Cocohoba, PharmD; Jason J. Schafer, PharmD
Jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.
This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Estimated time to complete activity: 1 hour
Jennifer Cocohoba, PharmD, BCPS, AAHIVP
Professor of Clinical Pharmacy
University of California San Francisco School of Pharmacy
Pharmacist, UCSF Women’s HIV Program
San Francisco, California
Jason J. Schafer, PharmD, MPH, BCPS AQ-ID, BCIDP, AAHIVP
Professor and Vice Chair
Department of Pharmacy Practice
Jefferson College of Pharmacy
Jefferson (Philadelphia University + Thomas Jefferson University)
This activity will present rapid antiretroviral therapy (ART) fundamentals and clinical benefits as well as strategies to link newly diagnosed HIV-positive patients to care quickly. Emphasis will be placed on the important role that pharmacists play as the trusted link between newly diagnosed patients and local treatment providers.
This activity is intended for clinical and community pharmacists involved in the care of patients with HIV infection.
Upon completion of this activity, participants should be better able to:
- Demonstrate knowledge of current HIV epidemiology and the critical role for rapid ART
- Select guideline-recommended ART regimens for use in current rapid ART
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-20-2204-H02-P)
Type of Activity: Application.
Instructions to Receive Credit
In order to receive credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity
- Complete the Preactivity Questions.
- Read or review the activity content.
- Complete the Postactivity Test Questions and Evaluation
- Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.
- Pharmacist learners must check the CPE Monitor for their credit within 60 days of the activity.
Disclosure of Conflicts of Interest
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this activity:
Jennifer Cocohoba, PharmD, BCPS, AAHIVP: Investigator initiated research/fellowship contract: Genentech, Inc. (fellowship program), ViiV Healthcare (grant pending)
Jason J. Schafer, PharmD, MPH, BCPS AQ-ID, BCIDP, AAHIVP Consulting fee: Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc.
The PIM and Integritas planners and managers hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. PIM and Integritas Communications do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee Information & Refund/Cancellation Policy
There is no registration fee for this educational activity.
Global Contact Information
For information about the accreditation of this program, please contact PIM via email at email@example.com or www.pimed.com
Microsoft Windows 2000 SE or above.
Internet Explorer (v5.5 or greater), Chrome or Firefox
MAC OS 10.2.8
Internet Explorer is not supported on the Macintosh.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
Maximizing Your Role to Impact Patient Outcomes